Study patients N = 11 | |
---|---|
Male sex, n (%) | 11 (100) |
Age (years) a | 35 (32–45) |
Body weight (kg) a | 56.1 (51.6–67.3) |
BMI (kg/m2) a | 18.2 (17.6–22.8) |
BSA (m2) | 1.69 (1.60–1.79) |
Serum creatinine (mg/dL) a | 0.80 (0.70–0.80) |
eGFR (mL/min · 1.73 m2) a | 96.1 (81.9–103.1) |
CKD stage, n (%) | |
1 | 7 (63.6) |
2 | 4 (36.4) |
3 | 0 (0) |
4 | 0 (0) |
5 | 0 (0) |
CD4+ cell count (/μL) a | 119 (37–211) |
HIV RNA viral load (log10/mL) a | 4.83 (4.61–5.85) |
Protease inhibitors (ritonavir-boosted), n (%) | 7 (63.6) |
Protease inhibitors (unboosted), n (%) | 0 (0) |
NNRTIs, n (%) | 0 (0) |
INSTIs, n (%) | 4 (36.4) |
Concurrent use of a nephrotoxic drug, n (%) | 4 (36.4) |
Hypertension, n (%) | 0 (0) |
Diabetes, n (%) | 0 (0) |
Hepatitis B, n (%) | 3 (27.3) |
Hepatitis C, n (%) | 0 (0) |
Plasma TFV concentration (ng/mL) a | 64.0 (56.0–90.5) |